南京招聘

We are an innovative biotechnology company located in Chengdu. We use antibody repertoire guided approach to discover and develop better antibodies with improved function - with the goal of improving patient outcomes and quality of life, and we have an excellent opportunity in the Discovery Biology Department for a principal scientist/group leader in Preclinical PK/PD/Toxicology. In this position, you will lead a group of associate scientists and participate in the design and execution of high quality preclinical PK/PD/Tox studies evaluating and informing lead candidate selection for engineered antibody therapeutics focused primarily, but not exclusively, on immuno-oncology. This role may also liaises with discovery and development project teams to design, analyze, and interpret in vivo studies performed at our own facility or contract laboratories.

Responsibilities
1. Interacts with other functional area experts in a project team to recommend the best course of preclinical development for a given program and defend those recommendations to management；
2. Designss appropriate PK/PD and toxicology studies to support large molecule drug development；
3. In partnership with a study monitor, provides scientific leadership, oversight and approval of studies implemented at our own or contract laboratories；
4. Analyzes and interprets results and makes recommendations to teams and senior management；
5. Prepares study reports and appropriate sections of the common technical documents for regulatory submission and queries on development candidates. Potentially interacts with health authorities；
6. Maintains current knowledge of the field and area(s) of scientific expertise and development；
7. Applies and/or procures appropriate platforms and strategies such as physiologically-based pharmacokinetic (PBPK) modeling and simulation, Non-Compartmental and Compartmental PK simulation.

Qualifications
1. PhD in Pharmacokinetics, Toxicology, or related science with a minimum of 2 years' experience in large molecule/biologics drug development；
2. Exceptional non-PhDs with demonstrated capabilities and/or significant experience may also be considered；
3. Experience sourcing and/or monitoring non-human primate preclinical projects at a contract laboratory is desirable；
4. Knowledge and experience in Good Laboratory Practices (GLPs) is preferred；
5. High functionality in MS Office (Word, Excel, Outlook, PowerPoint) and data analysis and graphing software (eg, GraphPad Prism, SpotFire, JMP)；
6. Exceptional verbal and written communication skills; ability to communicate clearly and effectively with scientific colleagues and management；
7. Must be able to demonstrate sound theoretical and experimental background in biology coupled with technical proficiency, scientific creativity, collaboration with others and independent thought；
8. Excellent organizational, documentation, negotiation and interpersonal skills; adaptive learning and critical thinking；
9. Thrives in an entrepreneurial environment with initiative and flexibility in delivering independent and matrixed team contributions.

四川汇宇制药股份有限公司 企业介绍

    四川汇宇制药股份有限公司生产基地位于四川省内江经济技术开发区内，占地面积10万平方米,项目总投资10亿元人民币，致力于高端抗肿瘤药物的研发，生产和销售。公司在四川成都双流区“天府国际生物城”设立全球创新药研发中心，将打造抗体抗癌创新药物研发总部及产业化基地，建设包括从事靶向抗肿瘤小分子化学药和大分子生物药研发、中试及产业化的研发中心，占地面积60亩，规划建筑面积88000平方米，可容纳1500名研发人员，计划在2022年建成运行。
    公司以科技创新为导向的发展理念，不断完善小分子化学药物和单克隆抗体生物药物两个技术平台，开发抗肿瘤领域的创新药物，公司一期项目可年产3000万瓶抗癌针剂，实现年产值25亿元人民币。公司的抗癌针剂于2014年通过英国GMP认证，并于同年顺利通过中国GMP认证。2015年7月公司获得欧盟药品放行资质，公司生产的抗癌针剂已经在伊丽莎白女王医院、皇家伦敦医院和剑桥大学附属医院等1200多家欧盟医院作为一线抗癌药物大规模使用。
    公司在美国、英国、法国、澳大利亚、加拿大、中国香港等全球80多个国家和地区建立了销售渠道并启动了当地的药品注册工作，已逐步建立并完善遍布全球的销售网络。同时以致力于改善人类健康为崇高宗旨，以‘关爱生命，追求卓越，简单诚信’为价值导向， 力争把公司打造成一家受人尊敬的国际化制药企业。